Skip to Content

Genetic Technologies Ltd ADR GENE

Morningstar Rating
$2.89 +0.08 (2.85%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

GENE is trading at a 53% discount.
Price
$2.56
Fair Value
$3.63
Uncertainty
Extreme
1-Star Price
$46.23
5-Star Price
$9.88
Economic Moat
Rrbx
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GENE is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.81
Day Range
$2.802.94
52-Week Range
$1.806.00
Bid/Ask
$2.87 / $2.89
Market Cap
$11.12 Mil
Volume/Avg
16,068 / 32,311

Key Statistics

Price/Earnings (Normalized)
7.07
Price/Sales
1.93
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Small Core
Total Number of Employees
60

Valuation

Metric
GENE
Price/Earnings (Normalized)
7.07
Price/Book Value
3.39
Price/Sales
1.93
Price/Cash Flow
Price/Earnings
GENE

Financial Strength

Metric
GENE
Quick Ratio
1.42
Current Ratio
1.67
Interest Coverage
−487.77
Quick Ratio
GENE

Profitability

Metric
GENE
Return on Assets (Normalized)
−73.31%
Return on Equity (Normalized)
−105.93%
Return on Invested Capital (Normalized)
−102.40%
Return on Assets
GENE
See how this stock stacks up to its competitors with Morningstar Investor

Diagnostics & Research Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
TMO
Thermo Fisher Scientific IncXzswwgqbCkfy$221.6 Bil
DHR
Danaher CorpLxjknrjmzWvhqt$184.7 Bil
IQV
IQVIA Holdings IncVkxswmzcVzlhfb$46.0 Bil
IDXX
IDEXX Laboratories IncMmhbflvqWsdffh$44.8 Bil
A
Agilent Technologies IncVdhkdbhwNtxxl$42.6 Bil
MTD
Mettler-Toledo International IncSdqcdszpymPfvjpt$28.5 Bil
ICLR
Icon PLCKrpmvzvWplfrz$27.7 Bil
ILMN
Illumina IncCrsrjcgzNqndbzv$21.8 Bil
WAT
Waters CorpCztklvfqVsw$20.4 Bil
LH
Laboratory Corp of America HoldingsXvgjsvjpqxWvzdbsd$18.4 Bil

Sponsor Center